ASH24,leusm,oncology,MedEd,MedTwitter – MashupMD

Mashup Score: 0

Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL - 11 hour(s) ago

Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.

Source: www.onclive.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- OncLive
  
  Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL @ASH_hematology #ASH24 #leusm #oncology #MedEd #MedTwitter https://t.co/XWxe1Nd1ib

Mashup Score: 2

Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL - 2 day(s) ago

Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.

Source: www.onclive.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- OncLive
  
  Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL @ASH_hematology #ASH24 #leusm #oncology #MedEd #MedTwitter https://t.co/XWxe1Nd1ib

Mashup Score: 2

Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL - 14 day(s) ago

Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.

Source: www.onclive.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- OncLive
  
  Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL @ASH_hematology #ASH24 #leusm #oncology #MedEd #MedTwitter https://t.co/XWxe1Nd1ib